stockrow
Saturday 7 November 2026
Export CARM’s income statement to Excel — free account
Carisma Therapeutics Inc.
CARM Healthcare Biotechnology
Carisma Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $19.6 million, up 31.6% from fiscal 2023.
- Revenue
- +392.0%
- EPS
- +445.2%
- Free cash flow
- +114.7%
Quarter to September 2025, against a year earlier
0.00
0.00
NaN
Follow CARM
Alert me
Carisma Therapeutics Inc. (CARM) P/E ratio
Carisma Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 29.4× (January 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 24.9× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2025 | 1.4× | — |
| Mar 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| 23 more quarters | Free account |
Against its own ten years
Low 0.0×
High 29.4×
Ten-year median
0.0×
Current reading's percentile
88
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CARM Carisma Therapeutics Inc. | n/m |
| PPCB Propanc Biopharma Inc compare | n/m |
| XRTX XORTX Therapeutics Inc. compare | n/m |
| GOVX GeoVax Labs Inc. compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| VRAX Virax Biolabs Group Limited compare | n/m |
| ITRMF Iterum Therapeutics PLC compare | n/m |
| OGEN Oragenics, Inc. compare | n/m |
| ABPO Abpro Holdings Inc. compare | 0.5× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)